Imsidolimab
ANB019-208
Phase 2 mab completed
Quick answer
Imsidolimab for Hidradenitis Suppurativa is a Phase 2 program (mab) at Vanda Pharmaceuticals Netherlands B.V. with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Vanda Pharmaceuticals Netherlands B.V.
- Indication
- Hidradenitis Suppurativa
- Phase
- Phase 2
- Modality
- mab
- Status
- completed